Insider · CIK 0001426344

Bertolino Arthur Peter

Reports to the SEC for 2 companies · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001426344

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-09-01	Innovation Pharmaceuticals Inc.F Tax Payment	Director, President and CMO	FTax Payment	−422K sh	$0.13	−$54.8K	2,059,316
2018-10-12	Innovation Pharmaceuticals Inc.F Tax Payment	Director, President and CMO	FTax Payment	−219K sh	$0.40	−$87.6K	2,480,927
2018-09-01	Innovation Pharmaceuticals Inc.Employee Stock Option (right to buy)A Award	Director, President and CMO	AAward	+618K sh	—	—	617,839
2018-09-01	Innovation Pharmaceuticals Inc.A Award	Director, President and CMO	AAward	+1.07M sh	—	—	2,699,873
2017-12-22	Innovation Pharmaceuticals Inc.F Tax Payment	Director, President and CMO	FTax Payment	−238K sh	$0.70	−$167K	1,633,206
2017-09-01	Innovation Pharmaceuticals Inc.A Award	Director, President and CMO	AAward	+1.07M sh	—	—	1,871,254
2017-09-01	Innovation Pharmaceuticals Inc.Employee Stock Option (right to buy)A Award	Director, President and CMO	AAward	+618K sh	—	—	617,839
2017-06-27	Innovation Pharmaceuticals Inc.F Tax Payment	Director, President and CMO	FTax Payment	−262K sh	$0.84	−$220K	804,587
2016-06-30	Innovation Pharmaceuticals Inc.A Award	Director, President and CMO	AAward	+1.07M sh	—	—	1,066,667
2016-06-30	Innovation Pharmaceuticals Inc.Stock OptionA Award	Director, President and CMO	AAward	+618K sh	—	—	617,839
2015-11-17	Revance Therapeutics, Inc.S Sale	EVP and Chief Medical Officer	SSale	−5,425 sh	$39.11	−$212K	36,329
2015-11-17	Revance Therapeutics, Inc.S Sale	EVP and Chief Medical Officer	SSale	−36 sh	$39.55	−$1,423.8	36,293
2015-11-17	Revance Therapeutics, Inc.S Sale	EVP and Chief Medical Officer	SSale	−2,277 sh	$39.11	−$89.1K	34,016
2015-11-17	Revance Therapeutics, Inc.S Sale	EVP and Chief Medical Officer	SSale	−15 sh	$39.55	−$593.25	34,001
2015-09-02	Revance Therapeutics, Inc.F Tax Payment	EVP and Chief Medical Officer	FTax Payment	−3,699 sh	$30.48	−$113K	41,754
2015-01-28	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	EVP and Chief Medical Officer	AAward	+34.4K sh	—	—	34,445
2015-01-28	Revance Therapeutics, Inc.A Award	EVP and Chief Medical Officer	AAward	+6,078 sh	—	—	45,453
2014-09-02	Revance Therapeutics, Inc.A Award	EVP and Chief Medical Officer	AAward	+39.4K sh	—	—	39,375
2014-09-02	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	EVP and Chief Medical Officer	AAward	+118K sh	—	—	118,125

Recent filings

Accepted (ET)
Sep 64
Bertolino Arthur Peter0001123292-19-001106
SEC(opens sec.gov)
Oct 154
Bertolino Arthur Peter0001123292-18-001005
SEC(opens sec.gov)
Sep 244
Bertolino Arthur Peter0001123292-18-000972
SEC(opens sec.gov)
Dec 274
Bertolino Arthur Peter0001477932-17-006280
SEC(opens sec.gov)
Sep 64
Bertolino Arthur Peter0001123292-17-001401
SEC(opens sec.gov)
Aug 85
Bertolino Arthur Peter0001477932-17-003733
SEC(opens sec.gov)
Jul 74
Cellceutix CORP0001477932-16-011219
SEC(opens sec.gov)
Nov 174
Revance Therapeutics, Inc.0001209191-15-080796
SEC(opens sec.gov)
Sep 44
Revance Therapeutics, Inc.0001209191-15-069655
SEC(opens sec.gov)
Jan 304
Revance Therapeutics, Inc.0001209191-15-008043
SEC(opens sec.gov)
Sep 24
Revance Therapeutics, Inc.0001209191-14-055321
SEC(opens sec.gov)

Companies

Address

C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD

NEWARK, CA, 94560